key: cord-0756074-kskuz1ug
authors: Hage, René; Schuurmans, Macé M.
title: 444Calcineurin Inhibitors and COVID-19
date: 2020-09-24
journal: Reumatol Clin
DOI: 10.1016/j.reuma.2020.09.001
sha: 49b30d5e9d93d0ef89f150b66f236e4097ce8f57
doc_id: 756074
cord_uid: kskuz1ug

nan

Secondly, the inhibiting effect of CNIs on viral replication of other coronaviruses has been demonstrated in some studies. In vitro studies showed effectiveness of CsA in some coronaviruses 5, 6 . Tacrolimus has been suggested to be effective for disease caused by the MERS-CoV 7 .

Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia

Biologic Therapy in COVID-19. Archivos de Bronconeumologia

Calcineurin inhibitors revisited: A new paradigm for COVID-19? The Brazilian Journal of Infectious Diseases

COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review

Suppression of coronavirus replication by cyclophilin inhibitors

Cyclosporin A inhibits the replication of diverse coronaviruses

MERS CoV infection in two renal transplant recipients: Case report

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury (TACROVID)